Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Titan Biotech's Board approved audited standalone financial results for FY ended March 2026 showing strong growth. Total income rose to Rs 2,116.01 crore from Rs 1,603.63 crore in the previous year, a 32% increase. Net profit jumped 50% to Rs 274.47 lakh from Rs 182.71 lakh year-on-year. Basic EPS improved from Rs 4.42 to Rs 6.64 per share. The Board also recommended a dividend of Rs 0.50 per equity share, subject to shareholder approval at the 34th AGM. Additionally, the company completed a 1:5 share split in February 2026, reducing face value from Rs 10 to Rs 2 per share, increasing shares from 82.64 lakh to 4.13 crore. Cost Auditor M/s Sanjay Kumar Garg & Associates was reappointed for FY 2026-27. The audit report is unqualified.
Strong financial performance with 50% profit growth and improved EPS is positive for shareholders. The share split makes the stock more affordable and liquid. Dividend recommendation provides income to shareholders. Unqualified audit opinion indicates clean financials with no concerns.